 |
PDBsum entry 4ojf
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immune system
|
PDB id
|
|
|
|
4ojf
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
|
|
Key reference
|
|
|
Title
|
|
Crystallization and preliminary X-Ray diffraction analysis of the FAB portion of the alzheimer'S disease immunotherapy candidate bapineuzumab complexed with amyloid-β.
|
|
|
Authors
|
|
G.A.Crespi,
D.B.Ascher,
M.W.Parker,
L.A.Miles.
|
|
|
Ref.
|
|
Acta Crystallogr F Struct Biol Commun, 2014,
70,
374-377.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
Bapineuzumab (AAB-001) and its derivative (AAB-003) are humanized versions of
the anti-Aβ murine antibody 3D6 and are immunotherapy candidates in Alzheimer's
disease. The common Fab fragment of these immunotherapies has been expressed,
purified and crystallized in complex with β-amyloid peptides (residues 1-8 and
1-28). Diffraction data at high resolution were acquired from crystals of
Fab-Aβ8 (2.0 Å) and Fab-Aβ28 (2.2 Å) complexes at the Australian
Synchrotron. Both crystal forms belonged to the primitive orthorhombic space
group P21221.
|
|
|
Secondary reference #1
|
|
|
Title
|
|
Bapineuzumab captures the n-Terminus of the alzheimer'S disease amyloid-Beta peptide in a helical conformation.
|
|
|
Authors
|
|
L.A.Miles,
G.A.Crespi,
L.Doughty,
M.W.Parker.
|
|
|
Ref.
|
|
Sci Rep, 2013,
3,
1302.
|
|
|
PubMed id
|
|
|
|
|
|
|
|
|
|
|
|
|
